194 related articles for article (PubMed ID: 36536539)
1. Prognostic value of RILPL2 and its correlation with tumor immune microenvironment and glycolysis in non-small cell lung cancer.
Chen D; Zhang H; Zhao L; Liu X; Xue S; Wu P; Jiang H
Cell Cycle; 2023 Apr; 22(7):841-857. PubMed ID: 36536539
[TBL] [Abstract][Full Text] [Related]
2. System analysis of
Situ Y; Gao R; Lei L; Deng L; Xu Q; Shao Z
Int J Biol Markers; 2022 Jun; 37(2):158-169. PubMed ID: 35254116
[TBL] [Abstract][Full Text] [Related]
3. Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma.
Yang L; He YT; Dong S; Wei XW; Chen ZH; Zhang B; Chen WD; Yang XR; Wang F; Shang XM; Zhong WZ; Wu YL; Zhou Q
J Immunother Cancer; 2022 Jan; 10(2):. PubMed ID: 35140113
[TBL] [Abstract][Full Text] [Related]
4. Role of ALOX5 in non-small cell lung cancer: A potential therapeutic target associated with immune cell infiltration.
Zhao Q; Sun Z; Pan Y; Jing Q; Li W; Wang C
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Mar; 48(3):311-322. PubMed ID: 37164914
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and Immunological Role of FAT Family Genes in Non-Small Cell Lung Cancer.
Feng Z; Yin Y; Liu B; Zheng Y; Shi D; Zhang H; Qin J
Cancer Control; 2022; 29():10732748221076682. PubMed ID: 35212236
[TBL] [Abstract][Full Text] [Related]
6. Protein phosphatase 1 regulatory subunit 3G (PPP1R3G) correlates with poor prognosis and immune infiltration in lung adenocarcinoma.
Zhuo X; Chen L; Lai Z; Liu J; Li S; Hu A; Lin Y
Bioengineered; 2021 Dec; 12(1):8336-8346. PubMed ID: 34592886
[TBL] [Abstract][Full Text] [Related]
7. Correlation between metastasis-associated gene 1 expression and tumor-associated macrophages in non-small cell lung cancer.
Ma K; Li YX; Guo QQ
Neoplasma; 2022 Sep; 69(5):1092-1100. PubMed ID: 35951452
[TBL] [Abstract][Full Text] [Related]
8. ZNF143 Expression is Associated with COPD and Tumor Microenvironment in Non-Small Cell Lung Cancer.
Feng Z; Yin Y; Liu B; Wang L; Chen M; Zhu Y; Zhang H; Sun D; Qin J
Int J Chron Obstruct Pulmon Dis; 2022; 17():685-700. PubMed ID: 35400998
[TBL] [Abstract][Full Text] [Related]
9. ERCC6L is a biomarker and therapeutic target for non-small cell lung adenocarcinoma.
Hou G; Lu Z; Bi Y; Deng J; Yang X
Med Oncol; 2022 Feb; 39(5):51. PubMed ID: 35150321
[TBL] [Abstract][Full Text] [Related]
10. NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis.
Liu XS; Zhou LM; Yuan LL; Gao Y; Kui XY; Liu XY; Pei ZJ
Front Immunol; 2021; 12():724741. PubMed ID: 34335635
[TBL] [Abstract][Full Text] [Related]
11. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
12. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.
Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J
BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014
[TBL] [Abstract][Full Text] [Related]
13. Programmed cell death ligand-1-mediated enhancement of hexokinase 2 expression is inversely related to T-cell effector gene expression in non-small-cell lung cancer.
Kim S; Jang JY; Koh J; Kwon D; Kim YA; Paeng JC; Ock CY; Keam B; Kim M; Kim TM; Heo DS; Chung DH; Jeon YK
J Exp Clin Cancer Res; 2019 Nov; 38(1):462. PubMed ID: 31718692
[TBL] [Abstract][Full Text] [Related]
14. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
15. [Immune Microenvironment Comparation Study between EGFR Mutant and EGFR Wild Type Lung Adenocarcinoma Patients Based on TCGA Database].
Zhu G; Li Y; Shi R; Xu S; Zhang Z; Cao P; Chen C; Liu H; Chen J
Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):236-244. PubMed ID: 33910272
[TBL] [Abstract][Full Text] [Related]
16. Identification of the cell cycle characteristics of non-small cell lung cancer and its relationship with tumor immune microenvironment, cell death pathways, and metabolic reprogramming.
Cao S; Xiao S; Zhang J; Li S
Front Endocrinol (Lausanne); 2023; 14():1147366. PubMed ID: 37091844
[TBL] [Abstract][Full Text] [Related]
17. [CD45RO⁺ Memory T Lymphocytes As A Candidate Marker for Non-small Cell Lung Cancer].
Tan Q; Li H; Yu M; Tang X; Tan J; Zhang S; Wang J
Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):254-264. PubMed ID: 33910273
[TBL] [Abstract][Full Text] [Related]
18. The Combined Detection of Immune Genes for Predicting the Prognosis of Patients With Non-Small Cell Lung Cancer.
Tian WJ; Liu SS; Li BR
Technol Cancer Res Treat; 2020; 19():1533033820977504. PubMed ID: 33256552
[TBL] [Abstract][Full Text] [Related]
19. M6A regulator expression patterns predict the immune microenvironment and prognosis of non-small cell lung cancer.
Liu X; Ma C; Liu H; Sun Z; Luo J
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2803-2814. PubMed ID: 35596010
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
